Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors
January 22 2018 - 4:05PM
Business Wire
Dr. Dunsire Brings Deep Biopharmaceutical
Experience to Alexion’s Board
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that
Deborah Dunsire, M.D. has been appointed to the Company's Board of
Directors as a new independent director. Dr. Dunsire is a proven
leader in the biopharmaceutical industry with three decades of
experience and a successful track record of growing businesses,
fostering R&D and commercial development, and creating
shareholder value.
Dr. Dunsire served as President and Chief Executive Officer of
Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the
transformation of the company into a biotechnology industry leader.
Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led
the Novartis North America Oncology Business, which during her
ten-year tenure grew in revenues from $50 million to more than $2.2
billion, and she served for eight years with Sandoz AG. Dr. Dunsire
currently serves as President and Chief Executive Officer of Xtuit
Pharmaceuticals, Inc., a privately held biopharmaceutical company
developing novel therapeutics. Dr. Dunsire also serves on the
boards of Xtuit and Ultragenyx Pharmaceutical, Inc., and previously
served on the boards of Takeda Pharmaceuticals, Allergan, Inc. and
FORUM Pharmaceuticals, Inc. She received her medical degree from
the University of Witwatersrand, Johannesburg, South Africa.
David Brennan, Chairman of the Board, commented, “We are
delighted to welcome Deborah to Alexion’s Board of Directors. Her
experience will be highly valuable to our board as we continue to
position Alexion to deliver long-term growth and sustainable value
for our shareholders. Alexion has made excellent progress over the
past year, enhancing our corporate governance, refocusing our
business strategy and achieving important corporate milestones. We
look forward to working with Deborah as we continue to build on our
leadership in treating patients with rare diseases.”
Dr. Dunsire added: “Alexion is a world-class organization with
innovative therapies and proven leadership in treating patients
with rare diseases. I am excited to join the Alexion Board and look
forward to contributing to the Company’s continued success.”
“Elliott strongly supports Deborah’s appointment to the Alexion
Board,” said an Elliott spokesperson. “She is one of the
biopharmaceutical industry’s most respected leaders and brings
significant experience to the Board. This is another welcome step
by Alexion to build on its recent accomplishments and enhance value
creation for all shareholders.”
About Alexion
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the
innovation, development and commercialization of life-changing
therapies. Alexion is the global leader in complement inhibition
and has developed and commercializes the first and only approved
complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS),
and anti-acetylcholine receptor (AchR) antibody-positive
generalized myasthenia gravis (gMG). In addition, Alexion has two
highly innovative enzyme replacement therapies for patients with
life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency
(LAL-D). As the leader in complement biology for over 20 years,
Alexion focuses its research efforts on novel molecules and targets
in the complement cascade, and its development efforts on the core
therapeutic areas of hematology, nephrology, neurology, and
metabolic disorders. This press release and further information
about Alexion can be found at: www.alexion.com.
[ALXN-G]
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements often include words such
as "anticipate," "believe," "expect," "will," or similar
expressions. Forward-looking statements are subject to factors that
may cause Alexion's results and plans to differ from those
expected, including the risks set forth from time to time in
Alexion's filings with the U.S. Securities and Exchange Commission,
including but not limited to the risks discussed in Alexion's
Quarterly Report on Form 10-Q for the period ended September 30,
2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after
the date hereof, except when a duty arises under law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180122006487/en/
Alexion Pharmaceuticals, Inc.Media:Kim Diamond,
475-230-3775Executive Director, Corporate
CommunicationsorInvestors:Elena Ridloff, CFA, 475-230-3601Vice
President, Investor RelationsorCatherine Hu, 475-230-3599Director,
Investor Relations
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024